NSFL1C

Summary

NSFL1C (NSFL1 cofactor, HGNC:15912) is a protein-coding gene on chromosome 20p13, encoding NSFL1 cofactor p47 (Q9UNZ2). Reduces the ATPase activity of VCP.

N-ethylmaleimide-sensitive factor (NSF) and valosin-containing protein (p97) are two ATPases known to be involved in transport vesicle/target membrane fusion and fusions between membrane compartments. A trimer of the protein encoded by this gene binds a hexamer of cytosolic p97 and is required for p97-mediated regrowth of Golgi cisternae from mitotic Golgi fragments. Alternative splicing results in multiple transcript variants. A related pseudogene has been identified on chromosome 8.

Source: NCBI Gene 55968 — RefSeq curated summary.

At a glance

• Clinical variants (ClinVar): 57 total
• Druggable target: yes
• MANE Select transcript: NM_016143

Identifiers

Gene identifiers

Field	Value
HGNC ID	HGNC:15912
Approved symbol	NSFL1C
Name	NSFL1 cofactor
Location	20p13
Locus type	gene with protein product
Status	Approved
Aliases	dJ776F14.1, p47, UBXD10, UBX1, UBXN2C
Ensembl gene	ENSG00000088833
Ensembl biotype	protein_coding
OMIM	606610
Entrez	55968

Gene structure

Transcript identifiers

Ensembl transcripts: 23 — 13 protein_coding, 5 nonsense_mediated_decay, 3 retained_intron, 2 protein_coding_CDS_not_defined

ENST00000216879, ENST00000353088, ENST00000381653, ENST00000461211, ENST00000470376, ENST00000476071, ENST00000478168, ENST00000487086, ENST00000489203, ENST00000553571, ENST00000555359, ENST00000555568, ENST00000555944, ENST00000855884, ENST00000855885, ENST00000855886, ENST00000855887, ENST00000855888, ENST00000855889, ENST00000926113, ENST00000926114, ENST00000926115, ENST00000965405

RefSeq mRNA: 3 — MANE Select: NM_016143 NM_001206736, NM_016143, NM_018839

CCDS: CCDS13015, CCDS13016, CCDS56175

Canonical transcript exons

ENST00000216879 — 9 exons

Exon	Start	End
ENSE00001932603	1466720	1466849
ENSE00003467602	1453031	1453140
ENSE00003489786	1458200	1458274
ENSE00003574250	1454213	1454305
ENSE00003604686	1445666	1445830
ENSE00003628337	1464329	1464426
ENSE00003647951	1452493	1452630
ENSE00003671857	1454967	1455132
ENSE00003910285	1442166	1443911

Expression profiles

Bgee: expression breadth ubiquitous, 298 present calls, max score 96.79.

FANTOM5 (CAGE): breadth ubiquitous, TPM avg 36.7805 / max 229.6578, expressed in 1823 samples.

FANTOM5 promoters (4 alternative TSS)

Promoter ID	TPM avg	Samples expressed
186018	34.2950	1822
186019	2.0189	1244
186020	0.4070	101
186021	0.0596	20

Top tissues by expression

301 total, by Bgee expression score (0-100, higher = more expressed):

Tissue	Anatomy ID	Expression score	Quality
right adrenal gland	UBERON:0001233	96.79	gold quality
right adrenal gland cortex	UBERON:0035827	96.75	gold quality
left adrenal gland	UBERON:0001234	96.62	gold quality
gastrocnemius	UBERON:0001388	96.55	gold quality
adrenal gland	UBERON:0002369	96.44	gold quality
adrenal cortex	UBERON:0001235	96.40	gold quality
muscle of leg	UBERON:0001383	96.38	gold quality
left adrenal gland cortex	UBERON:0035825	96.37	gold quality
skin of leg	UBERON:0001511	96.31	gold quality
adrenal tissue	UBERON:0018303	96.18	gold quality
tibialis anterior	UBERON:0001385	96.02	gold quality
skin of abdomen	UBERON:0001416	96.02	gold quality
pigmented layer of retina	UBERON:0001782	95.97	gold quality
monocyte	CL:0000576	95.96	gold quality
retina	UBERON:0000966	95.95	gold quality
prefrontal cortex	UBERON:0000451	95.89	gold quality
C1 segment of cervical spinal cord	UBERON:0006469	95.78	gold quality
right frontal lobe	UBERON:0002810	95.74	gold quality
ganglionic eminence	UBERON:0004023	95.70	gold quality
hindlimb stylopod muscle	UBERON:0004252	95.70	gold quality
mononuclear cell	CL:0000842	95.68	gold quality
islet of Langerhans	UBERON:0000006	95.64	gold quality
cortical plate	UBERON:0005343	95.64	gold quality
leukocyte	CL:0000738	95.62	gold quality
blood	UBERON:0000178	95.59	gold quality
amygdala	UBERON:0001876	95.56	gold quality
popliteal artery	UBERON:0002250	95.53	gold quality
esophagus mucosa	UBERON:0002469	95.52	gold quality
tibial artery	UBERON:0007610	95.52	gold quality
granulocyte	CL:0000094	95.46	gold quality

Single-cell (SCXA)

Detected in 1 experiment(s), a significant marker in 1.

Experiment	Marker?	Max mean expression
E-ANND-3	no	0.00

Regulation

Is transcription factor: no

Upstream regulators (CollecTRI, top): SPI1

miRNA regulators (miRDB)

71 targeting NSFL1C, top 30 by miRDB confidence (max_score; target_count = how many genes the miRNA targets in total — lower means more specific):

miRNA	Max score	Avg score	miRNA target_count
HSA-MIR-1193	100.00	65.93	529
HSA-MIR-4533	100.00	69.48	2758
HSA-MIR-4692	100.00	67.32	2066
HSA-MIR-4514	99.99	67.10	1870
HSA-MIR-6888-3P	99.97	65.95	1170
HSA-MIR-570-3P	99.96	72.41	4910
HSA-MIR-335-3P	99.93	73.36	4958
HSA-MIR-221-5P	99.86	65.45	1052
HSA-MIR-8073	99.86	65.21	1118
HSA-MIR-765	99.84	68.24	2442
HSA-MIR-544A	99.84	68.66	1965
HSA-MIR-6739-5P	99.80	67.87	2806
HSA-MIR-3934-3P	99.76	65.51	1351
HSA-MIR-11181-3P	99.75	66.38	2205
HSA-MIR-6733-5P	99.74	67.94	2759
HSA-MIR-4428	99.73	66.41	1733
HSA-MIR-4719	99.73	72.10	3329
HSA-MIR-1827	99.63	68.57	3265
HSA-MIR-4328	99.57	71.06	4094
HSA-MIR-3153	99.55	67.59	2337
HSA-MIR-6722-3P	99.45	67.62	1919
HSA-MIR-6165	99.44	67.12	1389
HSA-MIR-2392	99.43	67.50	708
HSA-MIR-548B-3P	99.38	67.26	1000
HSA-MIR-6507-3P	99.35	67.32	1059
HSA-MIR-4311	99.31	70.47	3041
HSA-MIR-3678-3P	99.31	67.10	1432
HSA-MIR-3606-5P	99.31	69.67	1168
HSA-MIR-6731-5P	99.28	67.42	2375
HSA-MIR-8085	99.28	67.56	2362

Literature-anchored findings (GeneRIF, showing 8)

• Using shotgun mass spectrometry, we found this protein differentially expressed in the dorsolateral prefrontal cortex from patients with schizophrenia. (PMID:19165527)
• The binding of p47 to polyubiquitinated NEMO triggers the lysosomal degradation of NEMO, thereby inhibiting IKK activation. (PMID:22990857)
• human p37/p47 and their C. elegans orthologue UBXN-2 regulate centrosome function in prophase by limiting the recruitment of Aurora A (PMID:23649807)
• The present results for the first time demonstrate that BDNF induces NADPH oxidase -derived reactive oxygen species generation through activation of p47 phox in a TrkB receptor-dependent manner (PMID:24612679)
• p47 promotes, whereas SASK1 delays the degradation of a single ERAD substrate, alpha-TCR. Additionally, we found that SAKS1 selectively inhibits the degradation of ERAD substrates without affecting cytosolic proteasomal substrates. (PMID:27785701)
• Degradation of p47 by autophagy contributes to CADM1 overexpression in ATLL cells through the activation of NF-kappaB. (PMID:30837480)
• p97 and p47 function in membrane tethering in cooperation with FTCD during mitotic Golgi reassembly. (PMID:33555040)
• Translocator protein (18 kDa) regulates the microglial phenotype in Parkinson’s disease through P47. (PMID:35475466)

Cross-species orthologs

6 orthologs

Organism	Symbol	Gene ID
danio_rerio	nsfl1c	ENSDARG00000087640
mus_musculus	Nsfl1c	ENSMUSG00000027455
rattus_norvegicus	Nsfl1c	ENSRNOG00000008604
drosophila_melanogaster	p47	FBGN0033179
drosophila_melanogaster	CG42383	FBGN0259729
caenorhabditis_elegans		WBGENE00022381

Paralogs (3): UBXN11 (ENSG00000158062), UBXN2A (ENSG00000173960), UBXN2B (ENSG00000215114)

Protein

Protein identifiers

NSFL1 cofactor p47 — Q9UNZ2 (reviewed: Q9UNZ2)

Alternative names: UBX domain-containing protein 2C, p97 cofactor p47

All UniProt accessions (5): Q9UNZ2, F2Z2K0, G3V4V8, R4GMY2, R4GNE6

UniProt curated annotations — full annotation on UniProt →

Function. Reduces the ATPase activity of VCP. Necessary for the fragmentation of Golgi stacks during mitosis and for VCP-mediated reassembly of Golgi stacks after mitosis. May play a role in VCP-mediated formation of transitional endoplasmic reticulum (tER). Inhibits the activity of CTSL (in vitro). Together with UBXN2B/p37, regulates the centrosomal levels of kinase AURKA/Aurora A during mitotic progression by promoting AURKA removal from centrosomes in prophase. Also, regulates spindle orientation during mitosis.

Subunit / interactions. Part of a ternary complex containing STX5A, NSFL1C and VCP. NSFL1C forms a homotrimer that binds to one end of a VCP homohexamer. The complex binds to membranes enriched in phosphatidylethanolamine-containing lipids and promotes Golgi membrane fusion. Interaction with VCIP135 leads to dissociation of the complex via ATP hydrolysis by VCP. Binds ubiquitin and mono-ubiquitinated proteins via its N-terminal UBA-like domain when bound to VCP.

Subcellular location. Nucleus. Golgi apparatus. Golgi stack. Chromosome. Cytoplasm. Cytoskeleton. Microtubule organizing center. Centrosome.

Post-translational modifications. Phosphorylated during mitosis. Phosphorylation inhibits interaction with Golgi membranes and is required for the fragmentation of the Golgi stacks during mitosis.

Similarity. Belongs to the NSFL1C family.

Isoforms (4)

UniProt ID	Names	Canonical?
Q9UNZ2-1	1	yes
Q9UNZ2-4	2
Q9UNZ2-5	3
Q9UNZ2-6	4

RefSeq proteins (3): NP_001193665, NP_057227, NP_061327 (=MANE)

Domains & families (InterPro)

ID	Name	Type
IPR001012	UBX_dom	Domain
IPR009060	UBA-like_sf	Homologous_superfamily
IPR012989	SEP_domain	Domain
IPR029071	Ubiquitin-like_domsf	Homologous_superfamily
IPR036241	NSFL1C_SEP_dom_sf	Homologous_superfamily

Pfam: PF00789, PF08059, PF14555

UniProt features (42 total): strand 11, modified residue 8, helix 5, turn 4, splice variant 3, domain 2, region of interest 2, short sequence motif 2, compositionally biased region 2, chain 1, sequence variant 1, sequence conflict 1

Structure

Experimental structures (PDB)

3 structures.

PDB	Method	Resolution (Å)
8HRZ	X-RAY DIFFRACTION	2.7
9MPU	ELECTRON MICROSCOPY	4
1SS6	SOLUTION NMR

Predicted structure (AlphaFold)

Model	pLDDT	Fraction very-high
AF-Q9UNZ2-F1	74.70	0.13

Functional residue map

Curated UniProt residues grouped by drug-discovery relevance — catalytic, ligand-binding, modification, and mutation-validated positions. Source: UniProtKB sequence features.

Post-translational modifications (8): 102, 114, 140, 167, 176, 192, 272, 74

Function

Pathways and Gene Ontology

Reactome pathways

1 pathways

ID	Pathway
R-HSA-9013407	RHOH GTPase cycle

MSigDB gene sets: 198 (showing top): GOBP_ESTABLISHMENT_OF_SPINDLE_ORIENTATION, GOBP_PROTEIN_LOCALIZATION_TO_CYTOSKELETON, GOBP_NUCLEAR_MEMBRANE_REASSEMBLY, GOBP_ESTABLISHMENT_OR_MAINTENANCE_OF_CELL_POLARITY, GOBP_VACUOLE_ORGANIZATION, GOBP_MEMBRANE_BIOGENESIS, GOBP_SPINDLE_LOCALIZATION, GOBP_MEMBRANE_FUSION, GRAESSMANN_APOPTOSIS_BY_DOXORUBICIN_DN, GRAESSMANN_RESPONSE_TO_MC_AND_DOXORUBICIN_DN, GOBP_MACROMOLECULE_CATABOLIC_PROCESS, ACEVEDO_NORMAL_TISSUE_ADJACENT_TO_LIVER_TUMOR_DN, GOBP_NEGATIVE_REGULATION_OF_PROTEIN_LOCALIZATION, GOCC_MICROTUBULE_ORGANIZING_CENTER, GOBP_MACROAUTOPHAGY

GO Biological Process (9): autophagosome assembly (GO:0000045), establishment of mitotic spindle orientation (GO:0000132), ubiquitin-dependent protein catabolic process (GO:0006511), Golgi organization (GO:0007030), nuclear membrane reassembly (GO:0031468), proteasome-mediated ubiquitin-dependent protein catabolic process (GO:0043161), positive regulation of mitotic centrosome separation (GO:0046604), membrane fusion (GO:0061025), negative regulation of protein localization to centrosome (GO:1904780)

GO Molecular Function (3): lipid binding (GO:0008289), ubiquitin binding (GO:0043130), protein binding (GO:0005515)

GO Cellular Component (9): nucleus (GO:0005634), chromosome (GO:0005694), cytoplasm (GO:0005737), Golgi stack (GO:0005795), centrosome (GO:0005813), cytosol (GO:0005829), VCP-NSFL1C complex (GO:1990730), Golgi apparatus (GO:0005794), cytoskeleton (GO:0005856)

Reactome top-level categories

Rollup of top-1 pathways:

Category	Pathways
RHO GTPase cycle	1

GO top-level categories

Rollup of top GO terms by namespace:

Category	Terms
cytoplasm	3
binding	2
intracellular membrane-bounded organelle	2
intracellular membraneless organelle	2
cellular anatomical structure	2
Atg12 activating enzyme activity	1
protein-phosphatidylethanolamide deconjugating activity	1
Atg12 conjugating enzyme activity	1
Atg12 ligase activity	1
organelle assembly	1
Atg1/ULK1 kinase complex assembly	1
autophagosome organization	1
mitotic cell cycle	1
establishment of mitotic spindle localization	1
establishment of spindle orientation	1
protein ubiquitination	1
modification-dependent protein catabolic process	1
organelle organization	1
endomembrane system organization	1
membrane assembly	1
nuclear membrane organization	1
ubiquitin-dependent protein catabolic process	1
proteasomal protein catabolic process	1
mitotic centrosome separation	1
regulation of mitotic centrosome separation	1
positive regulation of cell cycle process	1
membrane organization	1
protein localization to centrosome	1
negative regulation of protein localization	1
regulation of protein localization to centrosome	1
ubiquitin-like protein binding	1
intracellular anatomical structure	1
Golgi apparatus subcompartment	1
centriole	1
microtubule organizing center	1
protein-containing complex	1
endomembrane system	1

Protein interactions and networks

STRING

1590 interactions, top by confidence (×1000):

Protein A	Protein B	Partner UniProt	Score
NSFL1C	VCP	P55072	937
NSFL1C	VCPIP1	Q96JH7	875
NSFL1C	STX5	Q13190	767
NSFL1C	UBXN6	Q9BZV1	702
NSFL1C	UBXN11	Q5T124	699
NSFL1C	UFD1	Q92890	682
NSFL1C	UBXN7	O94888	603
NSFL1C	NPLOC4	Q8TAT6	591
NSFL1C	UBXN1	Q04323	578
NSFL1C	ASPSCR1	Q9BZE9	548
NSFL1C	FAF1	Q9UNN5	540
NSFL1C	GABARAPL2	P60520	521
NSFL1C	F5GZY7	F5GZY7	519
NSFL1C	UBXN8	O00124	496
NSFL1C	BET1L	Q9NYM9	492
NSFL1C	DGLUCY	Q7Z3D6	492

IntAct

123 interactions, top by confidence:

A	B	Type	Score
VCP	NSFL1C	psi-mi:“MI:0915”(physical association)	0.970
NSFL1C	VCP	psi-mi:“MI:0915”(physical association)	0.970
VCP	NSFL1C	psi-mi:“MI:0407”(direct interaction)	0.970
VCP	NSFL1C	psi-mi:“MI:2364”(proximity)	0.970
NSFL1C	VCP	psi-mi:“MI:2364”(proximity)	0.970
NSFL1C	VCP	psi-mi:“MI:0914”(association)	0.970
MED4	MED19	psi-mi:“MI:2364”(proximity)	0.900
VCP	ATXN3	psi-mi:“MI:0914”(association)	0.830
CFTR	ESYT2	psi-mi:“MI:2364”(proximity)	0.710
VCP	UBXN8	psi-mi:“MI:0914”(association)	0.690
TARDBP	NSFL1C	psi-mi:“MI:0915”(physical association)	0.670
NUF2	SPC24	psi-mi:“MI:0914”(association)	0.530

BioGRID (273): NSFL1C (Two-hybrid), NSFL1C (Reconstituted Complex), VCP (Protein-peptide), NSFL1C (Two-hybrid), UBC (Affinity Capture-Western), UBC (Reconstituted Complex), VCP (Affinity Capture-Western), NSFL1C (Two-hybrid), NSFL1C (Reconstituted Complex), ITPA (Co-fractionation), NSFL1C (Co-fractionation), NSFL1C (Co-fractionation), NSFL1C (Co-fractionation), NSFL1C (Co-fractionation), NSFL1C (Co-fractionation)

ESM2 similar proteins: G5EES6, H2L056, O13900, O14048, O17850, O35987, O74498, P0C8Q0, P27692, P34223, P34631, P35728, P38349, P40087, P55034, P87157, Q06336, Q06682, Q09289, Q10410, Q12017, Q12229, Q3SZC4, Q45FF9, Q4PGU6, Q5R630, Q5RBG3, Q5XIR9, Q5ZK10, Q60XN1, Q6BK42, Q6CHI1, Q6CWW9, Q6FQE9, Q6FRZ5, Q6NQK0, Q754R2, Q756I2, Q759T6, Q7Y175

Diamond homologs: D3ZID8, O35987, P0C627, P34223, P68543, Q0KL01, Q0P3R5, Q14CS0, Q3SZC4, Q5RBG3, Q5ZK10, Q5ZLK2, Q7Y175, Q8RWU7, Q99KJ0, Q9CZ44, Q9SUG6, Q9UNZ2, Q9UT81, F4IXN6, P0C8Q0, Q54BQ5, Q9N2W5

SIGNOR signaling

2 interactions.

A	Effect	B	Mechanism
CDK1	“down-regulates activity”	NSFL1C	phosphorylation
NSFL1C	“down-regulates activity”	CTSL	binding

Enriched among interaction partners

Reactome pathways and GO biological processes over-represented among this gene’s 118 IntAct physical interaction partners (hypergeometric vs the genome-wide background, BH-FDR, gene-set size 15–500, ranked by fold). A functional readout of the neighbourhood — distinct from this gene’s own memberships above, and biased toward well-studied / hub proteins, so read it as themes rather than proof.

Reactome pathways:

Pathway	Partners	Fold	FDR
Programmed Cell Death	6	10.3×	7e-03
mRNA Splicing - Major Pathway	11	7.1×	2e-04

Disease & clinical

Clinical variants and AI predictions

ClinVar

57 variants total. Per-class counts are floors (≥ shown; pagination cap):

Classification	Count (floor)
Pathogenic	0
Likely pathogenic	0
Uncertain significance	38
Likely benign	2
Benign	1

Top pathogenic / likely-pathogenic (0)

SpliceAI

2248 predictions. Top by Δscore:

Variant	Effect	Δscore
20:1452490:TA:T	donor_loss	1.0000
20:1452626:CCTCC:C	acceptor_gain	1.0000
20:1452627:CTCC:C	acceptor_gain	1.0000
20:1452627:CTCCC:C	acceptor_gain	1.0000
20:1452628:TCC:T	acceptor_gain	1.0000
20:1452628:TCCCT:T	acceptor_gain	1.0000
20:1452629:CC:C	acceptor_gain	1.0000
20:1452629:CCC:C	acceptor_gain	1.0000
20:1452630:CC:C	acceptor_gain	1.0000
20:1452631:C:CC	acceptor_gain	1.0000
20:1452631:CTGT:C	acceptor_loss	1.0000
20:1452632:T:C	acceptor_loss	1.0000
20:1453027:TCA:T	donor_loss	1.0000
20:1453029:A:AC	donor_gain	1.0000
20:1453029:AC:A	donor_gain	1.0000
20:1453029:ACCC:A	donor_loss	1.0000
20:1453030:C:CC	donor_gain	1.0000
20:1453030:CC:C	donor_gain	1.0000
20:1453030:CCCT:C	donor_gain	1.0000
20:1453136:TGAAC:T	acceptor_gain	1.0000
20:1453137:GAAC:G	acceptor_gain	1.0000
20:1453138:AAC:A	acceptor_gain	1.0000
20:1453139:AC:A	acceptor_gain	1.0000
20:1453140:CC:C	acceptor_gain	1.0000
20:1453141:C:CC	acceptor_gain	1.0000
20:1453141:C:CG	acceptor_loss	1.0000
20:1453142:T:G	acceptor_loss	1.0000
20:1453143:G:GC	acceptor_gain	1.0000
20:1453146:A:AC	acceptor_gain	1.0000
20:1454206:CACT:C	donor_loss	1.0000

AlphaMissense

2436 scored. Top likely-pathogenic:

Variant	Protein change	am_pathogenicity
20:1443833:G:C	F343L	1.000
20:1443833:G:T	F343L	1.000
20:1443835:A:G	F343L	1.000
20:1452519:G:C	F253L	1.000
20:1452519:G:T	F253L	1.000
20:1452521:A:G	F253L	1.000
20:1452580:A:G	L233S	1.000
20:1452622:G:T	P219Q	1.000
20:1453040:A:T	I213N	1.000
20:1453105:G:C	F191L	1.000
20:1453105:G:T	F191L	1.000
20:1453106:A:G	F191S	1.000
20:1453107:A:G	F191L	1.000
20:1453109:C:T	G190E	1.000
20:1453119:A:G	W187R	1.000
20:1453119:A:T	W187R	1.000
20:1453121:A:G	L186P	1.000
20:1453127:A:G	L184S	1.000
20:1455034:G:T	A126D	1.000
20:1455043:A:G	F123S	1.000
20:1455046:A:G	L122P	1.000
20:1455094:A:C	I106S	1.000
20:1455094:A:T	I106N	1.000
20:1455103:C:T	G103E	1.000
20:1455104:C:G	G103R	1.000
20:1455104:C:T	G103R	1.000
20:1455118:C:T	G98D	1.000
20:1455119:C:G	G98R	1.000
20:1455121:C:T	G97E	1.000
20:1455122:C:A	G97W	1.000

dbSNP variants (sampled 300 via entrez): RS1000006974 (20:1447135 A>C), RS1000075141 (20:1464094 A>G), RS1000100019 (20:1459163 C>T), RS1000132572 (20:1459571 C>T), RS1000253025 (20:1452755 C>A,T), RS1000419469 (20:1446439 T>C,G), RS1000439617 (20:1465724 T>C), RS1000452025 (20:1446904 G>A), RS1000465676 (20:1465713 C>T), RS1000702182 (20:1454741 T>C), RS1000942004 (20:1442043 T>C), RS1000951612 (20:1442319 T>G), RS1000965864 (20:1448432 T>A), RS1000967187 (20:1461399 T>G), RS1001244164 (20:1443037 C>A)

Disease associations

OMIM: gene MIM:606610 | disease phenotypes:

GenCC curated gene-disease

Mondo (0):

Orphanet (0):

HPO phenotypes

0 total (0 of 0 shown, HPO-id order):

GWAS associations

0 associations (top):

Drugs & pharmacology

Drug and pharmacology data

Is drug target: yes

ChEMBL targets (1): CHEMBL6067304 (SINGLE PROTEIN)

PharmGKB: 1 entry (VIP=true, CPIC=false)

ChEMBL bioactivities

2 potent at pChembl≥5 of 2 total, top 2 by pChembl (potency: 10 = 0.1 nM, 6 = 1 µM).

pChembl	Type	Value	Unit	Molecule
7.07	Kd	84.98	nM	CHEMBL5653589
7.07	ED50	84.98	nM	CHEMBL5653589

PubChem BioAssay actives

1 with measured affinity, of 2 total; 1 most potent distinct compounds. Largely complementary to BindingDB; screening values are coarse (µM, 4 dp), so sub-nM hits tie at the floor.

Compound	Assay	Type	Value	Unit
4-methyl-3-[(2-methyl-6-pyridin-3-ylpyrazolo[3,4-d]pyrimidin-4-yl)amino]-N-[3-(trifluoromethyl)phenyl]benzamide	2148890: Binding affinity to human NSFL1C incubated for 45 mins by Kinobead based pull down assay	kd	0.0850	uM

CTD chemical–gene interactions

38 total (human), top 30 by PubMed support.

Chemical	Actions (top 5)	PubMed papers
sodium arsenite	increases expression, decreases expression, increases abundance	3
Valproic Acid	affects expression, affects cotreatment, increases expression	3
Cyclosporine	increases expression	3
cobaltous chloride	decreases expression, increases expression	2
Arsenic	increases abundance, increases expression, increases ubiquitination	2
Benzo(a)pyrene	affects cotreatment, decreases expression	2
FR900359	affects phosphorylation	1
bisphenol F	increases expression	1
methylmercuric chloride	increases expression	1
triphenyl phosphate	affects expression	1
bisphenol A	increases expression	1
pyrogallol 1,3-dimethyl ether	affects cotreatment, decreases expression, affects localization, increases expression	1
beta-lapachone	decreases expression	1
nickel sulfate	decreases expression	1
beta-methylcholine	affects expression	1
cylindrospermopsin	increases expression	1
4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide	affects cotreatment, increases expression	1
nutlin 3	affects cotreatment, increases secretion	1
bisphenol B	increases expression	1
abrine	increases expression	1
jinfukang	increases expression	1
LDN 193189	affects cotreatment, increases expression	1
Resveratrol	affects cotreatment, increases expression	1
Temozolomide	increases expression	1
Benztropine	decreases expression	1
Caffeine	affects phosphorylation	1
Dactinomycin	affects cotreatment, increases secretion	1
Furaldehyde	affects cotreatment, affects localization, decreases expression, increases expression	1
Hydralazine	affects cotreatment, increases expression	1
Ivermectin	decreases expression	1

ChEMBL screening assays

1 unique, capped per target: 1 binding

Representative assays (with source publication via chembl_document):

Assay ID	Type	Description	Source paper
CHEMBL5651932	Binding	Binding affinity to human NSFL1C incubated for 45 mins by Kinobead based pull down assay	NVP-BHG712: Effects of Regioisomers on the Affinity and Selectivity toward the EPHrin Family. — ChemMedChem

Clinical trials (associated diseases)

0 trials via MONDO — disease-level, not drug-specific.